How much cash does Zevra Therapeutics, Inc. generate?

Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.

What is Zevra Therapeutics, Inc.'s free cash flow?

After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.

Where does Zevra Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Zevra Therapeutics, Inc. ZVRA Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	$83.23M+179%	-$105.51M-129%	-$46.05M—	——
Depreciation and amortization	$4.05M-36.5%	$6.39M+535%	$1.01M+6.6%	$944K+267%
Stock-based compensation	$12.63M-15.2%	$14.91M+150%	$5.95M+38.7%	$4.29M+76.3%
Gain (loss) on sale of assets	——	$0—	——	——
Change in inventories	$1.31M-85.3%	$8.87M+4,408%	-$206K—	——
Change in accounts payable	-$16M—	——	$12.02M+284%	$3.13M—
Change in other assets	-$451K—	$0—	——	-$386K—
Change in other liabilities	-$1.16M-239%	$835K—	——	——
Other working capital changes	——	——	——	——
Non-cash operating lease expense	——	$552K—	——	——
Loss on extinguishment of debt	——	——	——	$0+100%
Change in operating lease liabilities	-$675K-7.8%	-$626K-42.6%	-$439K—	——
Change in receivables	——	——	——	$7.27M+792%
Net cash from operating activities	——	-$69.67M-108%	-$33.54M-79.2%	-$18.72M—
Capital expenditures	$866K—	$0-100%	$296K+218%	$93K-8.8%
Purchases of investments	$309.99M+653%	$41.16M-10.3%	$45.87M+92.3%	$23.86M+54.7%
Proceeds from maturities/sales of investments	$178.5M+614%	$25M—	——	——
Purchases of intangible assets	$0-100%	$6M—	$0—	——
Proceeds from sale of property, plant and equipment	——	——	——	——
Acquired in-process research and development	——	——	——	——
Net cash from investing activities	——	-$22.16M—	——	-$36.99M-138%
Repayments of debt	$0—	——	$17.74M—	$0—
Proceeds from issuance of common stock	$0—	——	$6.11M—	——
Taxes paid for net share settlement	——	——	——	——
Net cash from financing activities	$12.06M-85.3%	$82.11M+188%	$28.46M—	——
Effect of exchange rate changes on cash	——	$454K+932%	$44K-78.4%	$204K—
Net increase (decrease) in cash	$28.62M+409%	-$9.26M+58.7%	-$22.42M+52.2%	-$46.88M—
Interest paid	$5.33M+1.3%	$5.26M+1,054%	$456K+42.1%	$321K+47.2%
Accretion (Amortization) of Discounts and Premiums, Investments	$3.13M+251%	$890K—	$0—	——
Cash Paid To Settle Derivative Instrument and Payoff Premium	——	——	——	——
Consulting fees paid in common stock	——	——	——	——
Discount and rebate liabilities	——	——	——	——
Fair value adjustment related to investments	-$149K-928%	$18K+103%	-$613K—	——
Fair Value Adjustment Related To Derivative Instrument	——	——	——	——
Fair value adjustment related to warrant and CVR liability	-$2.18M—	——	——	——
Foreign currency remeasurement (loss) gain on debt	——	——	——	$91K—
Income tax expense	——	$15.37M—	$0—	——
Increase (Decrease) in Accounts and Other Receivables	——	——	——	$7.27M+792%
Operating lease liabilities	-$675K-7.8%	-$626K-42.6%	-$439K—	——
Increase (Decrease) in Operating Lease, Right-of-Use Asset	——	——	——	——
Other long-term liabilities	-$1.16M-239%	$835K—	——	——
Increase (Decrease) in Other Operating Assets	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	-$152K—	——
Increase Decrease In Royalties Payable	——	——	——	——
Inventory write-downs	$11.7M+104%	$5.75M—	$0—	——
Operating lease right-of-use asset amortization	——	$552K—	——	——
Payment of Paid-in-Kind Interest	——	——	——	——
Payments to Acquire Intangible Assets	$0-100%	$6M—	$0—	——
Payments to Acquire Other Investments	$309.99M+647%	$41.49M-9.4%	$45.81M—	——
Proceeds from disposition of marketable securities and other investments	$178.5M+614%	$25M—	——	——
Proceeds from disposals of property, plant and equipment	——	——	——	——
Payments Of Principal On Insurance, Financing Arrangements	——	——	——	——
Proceeds from exercises of stock options and other stock issuances	——	——	——	——
Proceeds From Warrant Exercises	——	——	——	$0-100%
Repayments of Debt	$0—	——	$17.74M—	$0—
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	$454K+932%	$44K-78.4%	$204K—
Increase Decrease In Operating Lease Liability	-$675K-7.8%	-$626K-42.6%	-$439K—	——
Leased assets obtained in exchange for finance lease liabilities	——	$419K—	$0—	——
Cash not yet received on sale of of future royalties, intellectual property, and other assets, net	——	——	——	——
Free cash flow	——	-$69.67M-106%	-$33.83M-79.9%	-$18.81M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Zevra Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Zevra Therapeutics, Inc. generate?: Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.
What is Zevra Therapeutics, Inc.'s free cash flow?: After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.
Where does Zevra Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.